TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy


Pushpakom, SP ORCID: 0000-0002-6682-4235, Kolamunnage-Dona, Ruwanthi ORCID: 0000-0003-3886-6208, Taylor, Claire, Foster, Terry ORCID: 0000-0001-7725-7902, Spowart, Cath, Garcia-Finana, M ORCID: 0000-0003-4939-0575, Kemp, GJ ORCID: 0000-0002-8324-9666, Jaki, Thomas, Khoo, SH ORCID: 0000-0002-2769-0967, Williamson, Paula ORCID: 0000-0001-9802-6636 et al (show 1 more authors) (2020) TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clinical Infectious Diseases, 70 (10). pp. 2062-2072.

[img] Text
TAILoR Manuscript _CID_Revised_CLEAN.docx - Author Accepted Manuscript
Download (185kB)

Abstract

Background Combination antiretroviral therapy results in metabolic abnormalities which increase cardiovascular disease risk. We evaluated whether telmisartan reduces insulin resistance in human immunodeficiency virus (HIV)–positive individuals on antiretrovirals. Methods We conducted a multicenter, randomized, open-label, dose-ranging controlled trial of telmisartan. Participants with HIV infection receiving combination antiretroviral therapy were randomized equally to either no intervention (control) or 20, 40, or 80 mg telmisartan once daily. The adaptive design allowed testing of all dose(s) of telmisartan in stage I, with the promising dose(s) being taken into stage II. The primary outcome measure was reduction in homeostasis model assessment of insulin resistance (HOMA-IR) at 24 weeks. Results A total of 377 patients were recruited. In stage I, 48, 49, 47, and 45 patients were randomized to control and 20, 40, and 80 mg telmisartan, respectively (total n = 189). At the interim analysis, 80 mg telmisartan was taken forward into stage II. At the end of stage II (n = 105, control; 106, 80-mg arm), there were no differences in HOMA-IR (estimated effect, 0.007; SE, 0.106) at 24 weeks between the telmisartan (80 mg) and nonintervention arms. Longitudinal analysis over 48 weeks showed no change in HOMA-IR, lipid or adipokine levels. There were significant (P ≤ .05), but marginal, improvements in revised Quantitative Insulin Sensitivity Check Index (QUICKI) (0.004) and plasma hs-CRP (−0.222 mg/L) and reduction in liver fat content (1.714 mean reduction; P = .005). Conclusions No significant effect of telmisartan was demonstrated on the primary outcome (HOMA-IR), but there were marginal improvements with some secondary outcome measures. Further studies in this population are warranted to identify novel strategies for preventing cardiovascular morbidity and mortality. Clinical Trial Registration ISRCTN registry (51069819).

Item Type: Article
Uncontrolled Keywords: HIV, Antiretroviral drugs, Insulin resistance, Metabolic disease, Telmisartan
Depositing User: Symplectic Admin
Date Deposited: 29 Jul 2019 08:46
Last Modified: 19 Jan 2023 00:36
DOI: 10.1093/cid/ciz589
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3050404
Dimensions
Altmetric
CORE (COnnecting REpositories)